Biotechnologies Aramis inc.: federal grants and contributions: 4 agreements; $40.3M value; 2 departments; 3 programs.
Assay record ASY-CA-0E0UR4Q15L · Cite as: Assay Systems, “Biotechnologies Aramis inc.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/biotechnologies-aramis-inc/
This project will advance the development of a plant-based influenza vaccine candidate and continue to grow and enhance its world-leading virus-like particle technology platform in Quebec, Canada. The project consists of restarting the acquired Medicago pilot facility The project’s work phase is scheduled to end on December 31, 2026.
This project aims to demonstrate multiproduct production using a plant-based bioproduction platform.
Development of a closed-environment plant production system for vaccine biomanufacturing to reduce the ecological footprint while preserving yields and product quality.
This project consists of evaluating a production platform in plants for the expression of Artificial Intelligence (AI)-enhanced antibodies for the treatment of various cancers.
All grants from Innovation, Science and Economic Development Canada
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.